All posts in General News

31 Mar

Launch of Capital H Active Fund

In Capital Raising,General News by SLM / March 31, 2021 / 0 Comments

SLM Corporate is delighted to announce that it has advised emerging fund manager Capital H Management on the successful launch and initial capital raise for Capital H Active Fund.

Capital H Active Fund (or “Active Fund”) is the second in the Capital H Management stable of funds, following the launch of Capital H Inception Fund (or “Inception Fund”) in June 2018.  Inception Fund has delivered a return (net of fees) of approx. 36% p.a. for the period from inception to 28th February 2021.

Capital H Active Fund will invest in undervalued securities, focussing on ASX-listed small and micro-cap companies, and then work to realise value in these companies through various activist strategies and campaigns.  Activism has been a significant contributor to the strong returns delivered by Inception Fund to date, and Active Fund represents the opportunity to invest in this strategy through a vehicle completely dedicated and focused on an active approach to investing.

Capital H Active Fund starts life with $8 million of seed investment, with the initial capital raise strongly support by a range of family offices and high net-worth investors from SLM’s investor network.

For further information, please contact Barry Lewin or Eugene Tong.

14 Oct

SLM advises ASX-listed global biopharmaceutical company Clinuvel Pharmaceuticals Limited (ASX: CUV) on updated remuneration arrangements for key executives

In Announcements,General News by SLM / October 14, 2019 / 0 Comments

SLM Corporate is pleased to announce that it has acted as independent adviser to the Remuneration Committee of the Board of Clinuvel Pharmaceuticals Limited in relation to the reasonableness of a proposed grant of performance rights to the Managing Director, and new remuneration arrangements for the Managing Director and Chief Financial Officer.

The proposed remuneration packages aimed to incentivise Clinuvel’s senior executives for achieving long term objectives, while awarding part of their incentives in Clinuvel equity in order to align their objectives and performance fully with the interests of the company’s shareholders.

SLM undertook benchmarking of the proposed packages against local and international comparable peers to Clinuvel, and also considered the experience of the executives and their track record of value creation for Clinuvel.  SLM’s findings and opinion as to the reasonableness of the proposed packages were presented to the Clinuvel Board’s Remuneration Committee.

Clinuvel is an ASX-listed global biopharmaceutical company focused on developing and delivering treatments for patients with a range of severe genetic and skin disorders.  The award of the proposed performance rights was conditional on the US Food and Drug Administration (“FDA”) approving Clinuvel’s lead drug, SCENESSE®, for distribution to EPP patients, to enter the US market.  This FDA approval was granted on 9th October 2019.

For further information on this matter please contact:

Barry Lewin

Managing Director

Ph: 03 9244 9644 or 0419 032493

Email: barry.lewin@slmcorporate.com.au

28 Jul

QuickFee Limited (ASX: QFE)

In Announcements,General News by SLM / July 28, 2019 / 0 Comments

SLM Corporate is pleased to have acted as corporate adviser to QuickFee Limited (“QFE” or “the Company”) in relation to its successful Initial Public Offering (IPO) and ASX listing (ASX: QFE).

QFE is a commercial finance and payment platform company which provides lending solutions to SME clients of professional services firms, with operations in Australia and the US.

Over the past year, SLM has worked closely with QFE, providing corporate advisory support as well as guidance and oversight during the prospectus due diligence process, to position the Company for a successful ASX listing. Upon listing, SLM’s Managing Director, Barry Lewin, has also agreed to join QFE’s Board as Independent Non-Executive Chairman.

Bell Potter Securities as Lead Manager raised $13.5 million under the IPO Share Offer, with QFE having a fully diluted market capitalisation upon listing of $32.3 million.  The offer was strongly supported by a range of institutional and sophisticated investors, with the funds raised being used by QFE to fund its customer acquisition drive and lending growth in both Australia and the US.

For further information on the above, please contact:

Barry Lewin
Managing Director
Ph: 03 9244 9644 or 0419 032493
Email: barry.lewin@slmcorporate.com.au

01 Feb

Valuation Update

I am delighted to welcome Jason So as a Manager at SLM Corporate. Jason joined us last December, and supports the continued growth of our valuation and expert report practice. This team is led by SLM Directors Kuo ning Ho and Shakeel Mohammed.

The team provides a range of valuation services to publicly listed and private companies and has experience in all sectors. Examples of our work include valuations for:

• Transactions (including internal restructuring)
• Director valuations (including asset impairment and IP valuations)
• Employee remuneration (share options, performance rights, loan shares)
• Expert reports for a range of purposes, including litigation

For further information, please contact Kuo ning Ho on 03 9244 9644 or Kuoning.Ho@slmcorporate.com.au

-->